Ribociclib-Induced Delayed Dermatological Reaction: Case Report of a Rare Adverse Effect and Review of Literature

Ribociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor approved in combination with endocrine-based therapy for the treatment of hormone receptor-positive (HR + )/human epidermal growth factor receptor 2-negative (HER2 − ) advanced or metastatic breast cancer. It can significantly pro...

Full description

Saved in:
Bibliographic Details
Main Authors: Bhavika Kothari, Pallavi Parab, Seema Gulia, Sushmita Rath, Sudeep Gupta
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd.
Series:Indian Journal of Medical and Paediatric Oncology
Subjects:
Online Access:http://www.thieme-connect.de/DOI/DOI?10.1055/s-0043-1766128
Tags: Add Tag
No Tags, Be the first to tag this record!